Home › Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015
 

Keywords :   


Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

2015-06-01 12:09:35| Logistics - Topix.net

Mirati Therapeutics, Inc. today presented data that demonstrated preliminary evidence of clinical activity from its investigational targeted tyrosine kinase inhibitor candidate, MGCD265, as part of the developmental therapeutics category at the 2015 American Society of Clinical Oncology Annual Meeting being held in Chicago from May 29-June 2, 2015. The Company also provided updates on its other targeted tyrosine kinase inhibitor, MGCD516, and spectrum-selective HDAC inhibitor, mocetinostat.

Tags: results presents preliminary inhibitor

Category:Transportation and Logistics

Latest from this category

All news
08.07Atlantic Tropical Weather Outlook
08.07Eastern North Pacific Tropical Weather Outlook
08.07Tropical Storm Beryl Storm Surge Watch/Warning Map
08.07Summary for Tropical Storm Beryl (AT2/AL022024)
08.07Tropical Storm Beryl Update Statement
08.07Tropical Storm Beryl Potential Storm Surge Flooding Map
08.07Tropical Storm Beryl Probabilistic Storm Surge Graphics
08.07Tropical Storm Beryl Forecast Discussion Number 40
Transportation and Logistics »
08.07Atlantic Tropical Weather Outlook
08.07Eastern North Pacific Tropical Weather Outlook
08.07Tropical Storm Beryl Storm Surge Watch/Warning Map
08.07Tropical Storm Beryl Update Statement
08.07Summary for Tropical Storm Beryl (AT2/AL022024)
08.07Jones Family of Companies Announces New Hires
08.07Lecta commits to renewable gas, decarbonization
08.07Register now for 2024 ISU McKean Swine Disease Conference
More »